These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31143480)

  • 1.
    Filip R; Goliat B; Dziechciaż M; Dąbrowski P; Osuchowski M; Paluszkiewicz P
    Case Rep Gastrointest Med; 2019; 2019():2091089. PubMed ID: 31143480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
    Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
    Front Immunol; 2018; 9():1700. PubMed ID: 30131801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy.
    Hoentjen F; Hanauer SB; Hart J; Rubin DT
    J Clin Gastroenterol; 2013 Jan; 47(1):52-7. PubMed ID: 22858512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introducing vedolizumab to clinical practice: who, when, and how?
    Bryant RV; Sandborn WJ; Travis SP
    J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.
    Cherry LN; Yunker NS; Lambert ER; Vaughan D; Lowe DK
    Ther Adv Chronic Dis; 2015 Sep; 6(5):224-33. PubMed ID: 26336591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis.
    Haga K; Shibuya T; Osada T; Sato S; Fukuo Y; Kobayashi O; Yamada T; Asaoka D; Ito K; Nomura K; Haraikawa M; Nomura O; Fukushima H; Murakami T; Ishikawa D; Hojo M; Nagahara A
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab.
    Scarozza P; Marafini I; Laudisi F; Troncone E; Schmitt H; Lenti MV; Costa S; Rocchetti I; De Cristofaro E; Salvatori S; Frezzati L; Di Sabatino A; Atreya R; Neurath MF; Calabrese E; Monteleone G
    J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32024071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse enteritis after colectomy for ulcerative colitis: two case reports and review of the literature.
    Corporaal S; Karrenbeld A; van der Linde K; Voskuil JH; Kleibeuker JH; Dijkstra G
    Eur J Gastroenterol Hepatol; 2009 Jun; 21(6):710-5. PubMed ID: 19282770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
    Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
    BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus Therapy for Ulcerative Colitis-Associated Post-Colectomy Enteritis.
    Rush B; Berger L; Rosenfeld G; Bressler B
    ACG Case Rep J; 2014 Oct; 2(1):33-5. PubMed ID: 26157899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
    Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
    Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
    Buer LCT; Moum BA; Cvancarova M; Warren DJ; Bolstad N; Medhus AW; Høivik ML
    Scand J Gastroenterol; 2019 Jan; 54(1):41-48. PubMed ID: 30650312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.
    Chan W; Lynch N; Bampton P; Chang J; Chung A; Florin T; Hetzel DJ; Jakobovits S; Moore G; Pavli P; Radford-Smith G; Thin L; Baraty B; Haifer C; Yau Y; Leong RWL
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):735-740. PubMed ID: 29727386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
    Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
    J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Features and Therapeutic Outcomes of Post-colectomy Enteritis with Ulcerative Colitis.
    Horio Y; Uchino M; Hori K; Kusunoki K; Minagawa T; Kuwahara R; Kataoka K; Beppu N; Ikeda M; Ikeuchi H
    J Anus Rectum Colon; 2021; 5(4):405-413. PubMed ID: 34746505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.